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Abstract
BACKGROUND—Intravenous iron is used widely in hemodialysis, yet there are limited data on 
the effectiveness of contemporary dosing strategies or formulation type.
METHODS—We conducted a retrospective cohort study using data from the clinical database of 
a large dialysis provider (years 2004–2008) merged with administrative data from the United 
States Renal Data System to compare the effects of intravenous iron use on anemia management. 
Dosing comparisons were (1) bolus (consecutive doses ≥100 mg exceeding 600 mg during one 
month) versus maintenance (all other iron doses during the month); and (2) high (> 200 mg over 1 
month) versus low dose (≤200 mg over 1 month). Formulation comparison was administration of 
ferric gluconate versus iron sucrose over one month. Outcomes were hemoglobin, epoetin dose, 
transferrin saturation, and serum ferritin during 6 weeks of follow-up.
RESULTS—We identified 117,050 patients for the dosing comparison, and 66,207 patients for 
the formulation comparison. Bolus dosing was associated with higher average adjusted 
hemoglobin (+0.23 g/dl, 95% C.I. 0.21–0.26), transferrin saturation (+3.31% 95% C.I. 2.99–3.63), 
serum ferritin (+151 mcg/L, 95% C.I. 134.9–168.7), and lower average epoetin dose (-464 units 
95% C.I. -583 to -343) compared to maintenance. Similar trends were observed with high dose 
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iron versus low dose. Iron sucrose was associated with higher adjusted average hemoglobin (+0.16 
g/dl, 95% C.I. 0.12–0.19) versus ferric gluconate.
CONCLUSIONS—Strategies favoring large doses of intravenous iron or iron sucrose lead to 
improved measures of anemia management. These potential benefits should be weighed against 
risks, which currently, remain incompletely characterized.
INTRODUCTION
Intravenous (IV) iron is now an integral component of anemia management among patients 
with end-stage renal disease.1 Originally considered an adjuvant to erythropoeisis 
stimulating agents (ESA), its use has steadily risen over the past decade.2 In the United 
States, contemporary practice patterns for IV iron vary by both dose and formulation. For 
example, some dialysis clinics administer large repletion or bolus doses of iron over 
consecutive dialysis sessions on an intermittent, as-needed basis.3 Others provide low-dose 
administrations of iron every 1 to 2 weeks to maintain iron stores4, or a combination of 
maintenance and bolus dosing.3 Formulation patterns for intravenous iron primarily consist 
of iron sucrose and ferric gluconate despite the availability of five different agents. Both 
formulations are iron-carbohydrate complexes, but possess varying pharmacokinetic and 
pharmacodynamic properties that may differentially affect anemia management.5–7
Despite the growing use of iron, there are sparse contemporary data about the benefits of IV 
iron use in the US dialysis population. Previous studies of dosing patterns have not directly 
compared dosing strategies that are now used in practice. 8,9 Furthermore, they have limited 
sample size and follow-up, potentially reducing generalizability to patients currently 
receiving dialysis. Studies comparing ferric gluconate and iron sucrose have similar 
limitations.10,11
To address this gap in the literature, we conducted a large-scale observational study using 
data from one of the largest national dialysis providers linked with the United States Renal 
Data System (USRDS). Our goal was to examine the comparative effectiveness of dosing 
strategies and formulation types on clinical parameters of anemia management – 
hemoglobin level, epoetin alfa (EPO) dose, transferrin saturation (TSAT), and serum ferritin 
-- in a cohort that is representative of contemporary patients receiving hemodialysis.
METHODS
Data Sources
The data used for this study came from the clinical research database of a large dialysis 
provider and the United States Renal Data System (USRDS). The dialysis provider owns 
and manages over 1,500 outpatient dialysis facilities located throughout the U.S. in urban, 
rural, and suburban areas. Their clinical database captures detailed clinical, laboratory, and 
treatment data on patients receiving care at all of their dialysis units. All data are collected 
using standardized electronic health record systems. For this study, we used the clinical data 
to obtain detailed information on iron formulation and dosing, ESA use and dosing, and 
clinical laboratory values (e.g., hemoglobin, transferrin saturation, serum ferritin). We also 
used data from the USRDS, a national data system that collects, analyzes, and distributes 
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information about the treatment of ESRD in the U.S. Funded by the National Institutes of 
Diabetes Digestive and Kidney disease, the USRDS collaborates with several entities, 
including the Centers for Medicare and Medicaid Services (CMS), to create a detailed data 
system on ESRD patients. Our USRDS data originated from CMS and included data from 
the Medical Evidence Report Form, the Medicare Enrollment database, the ESRD Death 
Notification Form, and the standard analytic files, which contain final action claims data.12
We examined 5 years of data (2004 – 2008) from the clinical database to identify the cohort. 
These data were merged with data from the USRDS to obtain information on demographic 
characteristics, health care use (e.g., hospitalizations, outpatient care), and additional clinical 
characteristics (e.g., comorbidities).
Study Design
We utilized a retrospective cohort design in which we established a 6-month baseline period 
(to identify potential confounders and effect modifiers), a one-month iron exposure period, 
and a 6 week follow-up period. Figure 1 diagrams our specific implementation of the cohort 
design. The index date of the exposure period was anchored on a TSAT lab, as this 
information is used to guide iron administration.
Cohort Identification
Figure 2 outlines the creation of our sample. We considered a mix of incident and prevalent 
patients. After merging the clinical and USRDS data, we identified individuals who had one 
or more TSAT labs between January 30, 2004 and November 30, 2008. The January 30th 
date was chosen to allow for a month of dialysis, which is typically followed by a TSAT lab. 
The November 30th date was chosen to allow for the 1-month exposure period and at least 
one day of follow-up (December 31, 2008).
Data on TSAT labs were excluded if the patient: 1) had a dialysis vintage less than 9 months 
(which accounted for the 6-month baseline period and an additional 3 months from the start 
of dialysis to allow for stability in the CMS claims processing)12; 2) was not in center 
hemodialysis for the baseline and exposure period; 3) did not have Medicare Part A and Part 
B coverage; 4) received iron dextran or both ferric gluconate and iron sucrose in the 
exposure period; 5) had an insufficient amount of Part A claims at baseline (i.e., <120 days 
of Part A claims), suggesting incomplete data; 6) had polycystic kidney disease; and 7) had 
fewer than 9 dialysis sessions in the last month of baseline or during the exposure period. 
The last exclusion criterion was set to eliminate potential bias since individuals who did not 
receive the usual number of dialysis treatments in the month may have been too sick to do 
so. We also excluded TSAT records with missing covariate information. The exposure 
assessment period for each patient was anchored on the first qualifying TSAT lab.
Study Variables
Exposures—There were two primary exposures of interest: (1) dosing pattern, and (2) 
formulation type.
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For the dosing pattern comparison, the exposures were high dose versus low dose iron, and 
bolus versus maintenance dosing. Based on the distribution of the IV iron dosing, we 
defined high dose as >200 mg of IV iron in the one month exposure period. Low dose was 
defined as ≤200 mg of IV iron. We also created a no iron category for individuals who 
received no iron during the one month exposure period.
A month was classified as a "bolus month" if it contained administrations of iron on 
consecutive dialysis sessions of at least 100 mg. We also classified a month as a bolus month 
if it contained two or more administrations of iron >100mg that had the potential to exceed 
600mg within 30 days based on spacing between the doses in the sequence. For example, 
two consecutive iron doses of 200 mg each, within 10 days, would qualify as a bolus dose 
according to our definition. Months that had no bolus dosing patterns were classified as 
“maintenance months”. We also included a no iron category.
For the formulation comparison, the two exposures were iron sucrose and sodium ferric 
gluconate, measured using native codes from the clinical database. Individuals who received 
no iron were also included in the analyses.
Outcomes—We examined four clinical measures of anemia management during the 
follow-up period at a varying frequency: (1) weekly hemoglobin, (2) monthly TSAT, (3) 
monthly ferritin, and (4) weekly average EPO dose. All outcome variables were obtained 
from the clinical database.
Covariates—We included several covariates in our cohort analyses. The table in the 
Appendix presents specific definitions for the covariates, which included demographic and 
medical characteristics such as laboratory and anemia management variables, and co-
morbidity measures based on the Elixhauser classification.13 With an extensive list of co-
morbidities, we decided, a-priori, which ones to include in a parsimonious model, and others 
to add during sensitivity analyses.
Statistical Analysis
To assess the relation between the exposures (i.e., iron formulation and dosing practices) and 
the outcomes, (i.e., measures of anemia management) linear models estimated by 
Generalized Estimating Equations (GEE) were used. Covariates were grouped and entered 
consecutively into the model in the following manner using blocks of variables (Table 2, 
Appendix). Individuals were censored by death (for the hospitalization outcomes), loss to 
follow-up, receipt of a transplant, or administratively by the end of available data.
RESULTS
After merging clinical data with the USRDS, we identified a total of 117,050 patients who 
met our study entry requirements for the dosing comparison, and 66,207 patients for the 
formulation comparison. The patient characteristics of the primary cohort stratified by 
dosing pattern and formulation type are presented in Table 1. When comparing the high to 
low dose, approximately 29% of the sample received high dose iron, 34% received low dose 
iron, and 36% percent received no iron. In the bolus and maintenance comparisons, most 
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individuals received maintenance dosing (47.4 percent), with 16.3 percent receiving bolus 
dosing. The groups had generally similar covariate distributions, both in the high and low 
dose comparison and in the bolus and maintenance comparison, with some notable 
exceptions. For example, the mean hospital days in the past month were slightly higher for 
the bolus versus maintenance group. The frequency of historical infections was also greater 
in the high and bolus dose patients than in the low and maintenance dose patients, 
respectively. The majority of cohort participants were from the year 2004, the first year of 
the observation period, and included both prevalent and incident patients; in the subsequent 
years, only incident patients were included.
For the formulation cohort, a total of 32,156 patients comprised the iron sucrose group while 
8,149 patients made up the ferric gluconate group. The two groups had comparable 
distributions of race, gender, vintage, hospitalization rates, and baseline laboratory 
parameters. The baseline EPO and iron exposures were also similar between the two groups, 
as were the distributions of comorbidities. The ferric gluconate group, however, had a higher 
prevalence of catheter use, 33.2% versus 27.6%.
Tables 2 shows the results for the high versus low dose comparison with respect to anemia 
management parameters for the 1 month exposure and 6 week follow-up period. High dose 
of intravenous iron, compared with low iron dose, was associated with higher hemoglobin, 
TSAT, and ferritin, and with a lower EPO dose. Figures 3 & 4 display the average 
hemoglobin and EPO dose respectively for the high, low, and no iron dosing groups during 
the follow-up period. Bolus dosing of IV iron was associated with higher hemoglobin, 
TSAT, and ferritin, and lower EPO dose in weeks 4 and 6, compared to maintenance (Table 
3). Figures 5 & 6 display the average hemoglobin and EPO dose respectively for the bolus, 
maintenance, and no iron groups.
Table 4 displays the differences in the anemia management parameters for the formulation 
comparison. Ferric gluconate was associated with lower average hemoglobin than iron 
sucrose during the follow-up period. This difference was significant in all models, including 
the sensitivity analysis (results not shown). There were no significant differences in EPO 
dose, TSAT, or serum ferritin between the formulations in the fully adjusted model. Figures 
7 & 8 display the mean hemoglobin and EPO dose during the follow-up period for the two 
formulation groups.
The addition of the 5th covariate block for the purpose of sensitivity analysis, did not alter 
our findings for either dosing comparison (high versus low, or bolus versus maintenance) or 
for the formulations comparison (ferric gluconate versus iron sucrose), results not shown.
DISCUSSION
Among patients with ESRD anemia is a common condition14 that is associated with 
increased morbidity, mortality, and risk of hospitalization.15 Erythropoesis stimulating 
agents and intravenous iron have been used in combination to manage anemia. While recent 
clinical trial data have provided more precise information on the efficacy and safety of 
ESAs 16–18 contemporary data for intravenous iron is sparse.
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We therefore examined the comparative effectiveness of dose and formulation of intravenous 
iron on anemia management, using schedules and formulations reflective of current practice 
in the United States. Our data show that large doses of intravenous iron, whether bolus or 
high dose, are associated with higher hemoglobin, TSAT, and ferritin, and with lower ESA 
dose. We also found that iron sucrose is associated with higher level of hemoglobin 
compared to ferric gluconate. The findings for the dose and formulation comparisons did not 
change meaningfully with the addition of several sets of pre-specified covariates and 
potential confounders. To our knowledge, this is the largest study to compare intravenous 
iron either by dosing pattern or by formulation.
Previous studies of bolus dosing8.9 have demonstrated a similar beneficial effect on anemia 
parameters, albeit with markedly smaller numbers of patients. The patients included in our 
study cohort, furthermore, had numerous co-morbidities that are representative of the 
conditions patients who receive IV iron may have, including recent hospitalizations, 
infections, and catheters for dialysis access. Such patients are often excluded in clinical trials 
of intravenous iron, but may be especially sensitive to the effects of intravenous iron 
administration. This analysis furthermore suggested a dose response effect. Iron is essential 
in the production of the heterocyclic porphyrin ring of hemoglobin, and therefore, a 
relatively large iron dose should result in a higher hemoglobin value than a relatively small 
dose, as seen in our data. Bolus dosing was associated with a greater absolute increase in 
hemoglobin high dose IV iron (though not compared directly).
With respect to the formulation comparisons, two previous clinical trials comparing these 
iron sucrose and ferric gluconate did not find a statistically significant difference between 
the agents with respect to attained hemoglobin, TSAT, or ferritin values. 11,12 Interestingly, 
one of the studies reported that the attained hemoglobin value at 6 months in the iron sucrose 
group was 0.3 g/dl higher than in the ferric gluconate group, a difference that may not have 
reached statistical significance because of insufficient power. 11 Indeed, intrinsic differences 
in properties of the two agents could help explain our observations.5–7 Ferric gluconate is 
taken up quickly by the reticuloendothelial system (RES) and eliminated rapidly from the 
plasma, while iron sucrose is taken up more slowly and thus has a longer plasma half-life. 
Furthermore, iron sucrose has a lower binding coefficient than transferrin and there is a 
significant amount of direct transfer of iron from iron sucrose to transferrin in the 
plasma. 19,20
While the findings of the study ostensibly re-affirm current trends in clinical practice -- a 
trend for larger doses of iron, and predominance of iron sucrose-- they also indirectly raise 
questions about safety. The mean adjusted difference in achieved hemoglobin was only 0.2 
mg/dl between groups of patients receiving either high or bolus dosing, and those receiving 
low or maintenance dosing. This benefit comes at a potential cost, a 2 to 3 fold greater 
intravenous iron exposure. Experimental studies have demonstrated risk associated with 
intravenous iron21–24, though clinical studies have yet to clearly show an increased risk of 
infection25 or mortality.26,27 Recent clinical observations suggest that large doses of 
intravenous iron in the patients with chronic kidney disease results in radiographic evidence 
of excess tissue iron not detectable by serum laboratories. 28–30 The long-term effects of 
excess tissue iron from intravenous products are not known.
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The findings of this study should be interpreted in the context of the following limitations. 
First, our study was non-experimental and, therefore, could have been confounded by 
unobserved differences between users of the dosing strategies and formulations. We saw an 
increased prevalence of medical comorbidities among patients receiving either high or bolus 
dosing of iron. However, our robust sample size allowed us to control for a very large 
number of these covariables, and to perform sensitivity analyses. The point estimates did not 
significantly change the point estimates with either of these methods, suggesting that 
unobserved confounding may be minimal. Also, we saw little difference between the 
patients exposed to iron sucrose and those exposed to ferric gluconate. A second limitation 
is that our study design required survival until 9 months after the start of dialysis, which may 
have excluded patients with a high prevalence of serious co-morbidities. While excluding 
such patients may ultimately limit the generalizability of our results, it would allow for a 
more valid interpretation of the effect of exposure, intravenous iron, on the outcome, 
measures of anemia management. A third limitation to the current analysis is that relatively 
fewer individuals were available for the formulation comparison than for the dosing 
comparisons ( 66,207 versus 117,050). This is likely the result of a secular trend during the 
observation period when large dialysis organizations chose iron sucrose because of favorable 
pricing structures, intuitive dosing (multiples of 50 mg rather than 62.5 mg), and ease of 
administration (vials rather than glass ampules).
Nonetheless, the study findings may help inform decision making about iron management in 
an era of new incentives but minimal data from clinical trials. Dialysis providers and ESRD 
networks now face an environment of pay-for-performance, including expanded capitated 
reimbursement (the ESRD Prospective Payment System, which includes costs for ESAs and 
iron supplementation, but not blood transfusions) 31, a dynamic Quality Incentive Program 
that is mandated by law to include quality metrics on anemia32, and black box warnings 
about high hemoglobin levels33. In such a context, the study data favor a strategy of low or 
maintenance IV iron, as individuals given these doses would be, on average, less likely to 
have large or rapid increases in hemoglobin than if given bolus or high dose intravenous 
iron. The data also demonstrate that low and maintenance intravenous iron are associated 
with a higher epogen dose. Indeed, the data highlight the very real competing incentives that 
providers now face, minimizing operational costs by finding the “right mix” of ingredients 
for the treatment of anemia (ESAs, iron supplementation, blood transfusion) while 
maximizing patient safety. Maximizing the latter should be the undisputed and universal 
goal. In the absence of data on clinical safety of large doses of intravenous iron, furthermore, 
the prudent choice would be for moderation.34,35
In conclusion, our results suggest that large doses of intravenous iron lead to increased 
hemoglobin, improved iron status, and reduced epoetin dose. We also find that iron sucrose 
may be more effective than ferric gluconate with respect to hemoglobin outcomes. On-going 
research into the safety of intravenous iron dosing strategies and formulation choices will be 
crucial to help weigh the benefits of greater iron use, reported here, against its risks, which 
remain poorly quantified. Ultimately, a clinical trial comparing dose and formulation may be 
necessary.36
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Age Categorized as: 16–45; 46–60; 61–75; >75 yrs. USRDS
Sex Male or female USRDS
Race White, Black, Other USRDS
Medicaid Eligibility Indicator for dual eligibility during any part of 
the baseline
USRDS
Year of treatment 2004, 2005, 2006, 2007, 2008 Clinical Database
Census Region Based on location of last dialysis center in 




Vintage Categorized as 0; 1–3; 4 or more yrs. USRDS
ESRD Reason Diabetes, Glomerulonephritis, hypertension, 
other
USRDS
BMI Categorized as underweight, normal, 
overweight, obese
Clinical Database & USRDS
Anemia Management
Access Most recent vascular access (catheter vs fistula/
graft) prior to TSAT index date
Clinical Database
EPO dose (baseline) Total EPO dose, (quintiles) Clinical Database
EPO dose (exposure) Total EPO dose, (tertiles plus a no-use 
category)
Clinical Database
Index TSAT Last TSAT at baseline (quintiles) Clinical Database
Iron dose Total dose at last month of baseline, 
categorized as none, low (1–200 mg), or high 
(>200mg)
Clinical Database
Hemoglobin Most proximal Hb lab prior to index TSAT date 
(<10,10–11,>11–12,>12–13,>13)
Clinical Database
Ferritin Most proximal serum ferritin prior to index 
TSAT date (quintiles)
Clinical Database
Albumin At baseline (<3.3, 3.3–3.9, >3.9) Clinical Database
Comorbidities
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Hospital days in last month of 
baseline
Categorized as 0, 1–3, <=4 USRDS, Medicare Part A 
Claims
Infection in last month Any hospital admission in the last month with 
one of the following ICD-9-CM diagnostic 
codes as the principal diagnostic code: 001–
139, 254.1, 320–326, 331.81, 372– 372.39, 
373.0–373.2, 382–382.4, 383.0, 386.33, 
386.35, 388.60, 390–393, 421–421.1, 422.0, 
422.91–422.93, 460–466, 472–474.0, 475–
476.1, 478.21–478.24, 478.29, 480–490, 491.1, 
494, 510–511, 513.0, 518.6, 519.01, 522.5, 
522.7, 527.3, 528.3, 540–542, 566–567.9, 
569.5, 572–572.1, 573.1– 573.3, 575–575.12, 
590–590.9, 595–595.4, 597–597.89, 598, 
599.0, 601–601.9, 604–604.9, 607.1, 607.2, 
608.0, 608.4, 611.0, 614–616.1, 616.3–616.4, 
616.8, 670, 680–686.9, 706.0, 711–711.9, 730–
730.3, 730.8–730.9, 790.7–790.8, 996.60– 
996.69, 997.62, 998.5, and 999.3.
USRDS, Medicare Part A 
Claims
Any claims with the following HCPCS codes 
for antibiotic use in last month of baseline: 
J3370, J0690, J0713, J0692, J0696, J1580, 
J3260, J0278, J1840, J1956.
USRDS, Medicare Part A & B 
Claims
Any indication of IV antibiotic use in the last 
month of baseline.
Clinical Database
Pneumonia Any ICD-9-CM diagnostic code of 481.xx – 
486.xx in baseline period
USRDS, Medicare Part A & B 
Claims
Vascular Access Infection Any ICD-9-CM diagnostic code of 996.62 in 
baseline period
Sepsis Any ICD diagnostic code 038.xx, 995.90, 
995.91, 995.92 in baseline period
Diabetes Any ICD-9-CM diagnostic code of 250.xx in 
baseline period
Ischemic Stroke Any ICD-9-CM diagnostic code of 434.01, 
434.11, 434.91, 435, 436, 437, 438, V12.54 in 
baseline period
MI Any ICD-9-CM diagnostic code of 410.xx in 
baseline period
COPD Any ICD-9-CM diagnostic code of 
490.xx-496.xx, 505.xx, 506.4 in baseline period
Cancer Any ICD-9-CM diagnostic code of 173.3, 
173.9, 174.0–175.9, 179–195, 196–199, 232.9, 
233.0, 233.1, 300.29, 338.3, 789.51, 795.82, 
799.4, V67.2, 200, 201, 202.0–202.3, 202.50- 
203.01,203.8, 238.6, 273.3 in baseline period
GI bleeding Any ICD-9-CM diagnostic code of 578.xx in 
baseline period
Additional Comorbidities for Sensitivity Analyses
Pulmonary circulation disease Any ICD-9-CM diagnostic code of 
415.xx-417.xx in baseline period USRDS, Medicare Part A & B 
Claims
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Peptic Ulcer Disease Any ICD-9-CM diagnostic code of 530.2, 
531.xx-534.xx, V12.71 in baseline period
Liver disease Any ICD-9-CM diagnostic code of 070.32, 
070.33, 070.54, 456.0, 456.1, 456.20, 456.21, 
571.0, 571.2, 571.3, 571.4, 571.5, 571.6, 571.8, 
571.9, 572.3, 572.8, V42.7 in baseline period
Other neurological problem Any ICD-9-CM diagnostic code 331.9, 332.0, 
333.4, 333.5, 334–335, 340, 341, 345.0, 345.1, 
345.4, 345.5, 345.8, 345.9, 348.1, 348.3, 780.3, 
784.3 in baseline period
Substance abuse Any ICD-9-CM diagnostic code 303.xx-305.xx 
in baseline period
Ischemic Heart disease, other 
heart disease, peripheral vascular 
disease, history of CABG, Stent, 
PTCA
Any ICD-9-CM diagnostic code of 
411.xx-414.xx, 420.xx- 429.xx, 785.o, V45.0, 
v53.3, 402.11, 402.91, 404.11, 404.12, 404.91, 
404.93, 093.2, 746.3–746.6, v42.2, v43.3, 
v43.4441.xx- 443.xx, 447.1, 557.1, 557.9, 
444.xx-445.xx; Procedure codes of 00.66, 
92982, 92985, 36.06, 36.07, 92980, 33510–
33519 in baseline period
Hypertension Any ICD-9-CM diagnostic code of 
401.xx-405.xx, except 402.11, 402.91, 404.11, 
404.13, 404.91, 404.93 in baseline period
Rheumatic heart disease Any ICD-9-CM diagnostic code of 393.xx 
-398.xx in baseline period
Psychiatric problems Any ICD-9-CM diagnostic code 295.xx-298.xx 
in baseline period
Autoimmune disorders Any ICD-9-CM diagnostic code of 564.1, 
696.0, 696.1, 695.4, 710.0, 701.0, 710, 714, 
720, 725 in baseline period
Blood loss anemia Any ICD-9-CM diagnostic code of 280.0 in 
baseline period
Transfusion Indicator for receipt of one or more 
transfusions during the baseline period, based 
on HCPCS codes P9010, P9011, P9016, P9021, 
P9022, P9038, P9039, P9040, 36430 and ICD- 
9 codes 99.03, 99.04
Table 2
Groupings of variables (Block) used in models
Block Variables
1 Epogen (EPO) dose during exposure period
2 Block 1 & age, sex, race
3 Block 2 & baseline hemoglobin, ferritin, and index TSAT
4 (Fully adjusted model) Block 3 & pneumonia, vascular access infection, or sepsis in past 6 months; any infection 
in past month; most recent vascular access is catheter; vintage; baseline albumin; baseline 
EPO dose; baseline iron dose; history of diabetes, stroke, myocardial infarction, chronic 
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obstructive pulmonary disease, cancer, or gasterointestinal bleeding in past 6 months; 
number of hospital days in past month, and body mass index
5 (Sensitivity analysis) Block 4 & reason for ESRD (Diabetes,glomerulonephritis, hypertension, other); history of 
the following in the past 6 months: heart problems (combining ischemic heart disease, 
other heart, peripheral vascular disease, coronary artery bypass grafting/coronary artery 
stenting/percutaneous coronary angioplasty), hypertension, rheumatic heart disease, 
psychiatric problems, transfusion, autoimmune disorder, blood loss anemia, pulmonary 
circulation disease, ulcer, liver disease, other neurological problem, substance use.; year; 
geographic region; Medicaid eligibility
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Creation of Study Cohorts
Kshirsagar et al. Page 15














Average hemoglobin by dosing pattern of IV iron (Fully adjusted model).
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Average EPO dose by dosing pattern of IV iron (Fully adjusted model).
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Average hemoglobin by dosing pattern of IV iron (Fully adjusted model).
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Average EPO dose by dosing pattern of IV iron (Fully adjusted model).
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Average hemoglobin by formulation of IV iron (Fully adjusted model).
Kshirsagar et al. Page 20














Average EPO dose by formulation of IV iron (Fully adjusted model).
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